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Vertical Inhibition of the mTORC1/mTORC2/PI3K
Pathway Shows Synergistic Effects against Melanoma
In Vitro and In Vivo
Johannes Werzowa1, Stefan Koehrer1, Sabine Strommer1, Daniel Cejka1, Thorsten Fuereder1, Eva Zebedin2
and Volker Wacheck1,3
The phosphatidyl inositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway has been shown to be
involved in the development of melanoma. PI-103 is a kinase inhibitor blocking PI3K class IA and mTOR complex
1 and 2. Here, we studied the effect of targeting the PI3K/mTORC1/mTORC2 pathway by PI-103 and rapamycin in
melanoma cells and in a melanoma mouse model. Dual targeting of PI3K and mTOR by PI-103 induced apoptosis
and cell-cycle arrest, and inhibited viability of melanoma cells in vitro. Combined treatment with PI-103 and the
prototypic mTORC1 inhibitor rapamycin led to the synergistic suppression of AKT and ribosomal S6 protein
phosphorylation and to the induction of apoptosis. In vivo, PI-103 and rapamycin displayed only modest single-
agent activity, but the combination significantly reduced the tumor growth compared with both single agents.
These data show that blocking the PI3K/mTORC1/mTORC2 pathway using the combination of two distinct small-
molecule inhibitors (‘‘vertical inhibition’’) leads to superior efficacy against malignant melanoma in vitro and
in vivo.
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INTRODUCTION
The phosphatidyl inositol 3-kinase/mammalian target of
rapamycin (PI3K/mTOR) pathway has emerged as a promis-
ing target for anti-cancer therapies. PI3K and its downstream
targets AKT and mTOR have a central role not only in
physiological processes such as growth, survival, and
proliferation, but also in the development of malignant
disease (Bjornsti and Houghton, 2004; Samuels and Ericson,
2006). There are many possible mechanisms that can lead to
aberrant activation of this pathway, such as mutations of
growth factor receptors, PI3K, phosphatase and tensin
homolog deleted on chromosome 10 (PTEN), 3-phosphoino-
sitide-dependent kinase 1, RAS, tuberous sclerosis protein 1
and 2 (TSC1/2), and AKT (Samuels and Ericson, 2006).
PI3K proteins form a family that is divided into three
classes. In regulating proliferation and tumorigenesis, the
most important PI3K proteins are those that belong to class
IA. Class IA PI3Ks have a catalytic subunit consisting either of
p110a, b, or d. p110a is the primary insulin responsive PI3K
via its close association with insulin receptor substrate-1, and
has been linked to solid cancers (Knight et al., 2006; Denley
et al., 2007). Signaling via p110a leads to phosphorylation
and activation of proteins containing a pleckstrin homology
domain. Among these are the serine/threonine kinase AKT
and its activating kinase 3-phosphoinositide-dependent
kinase 1 (Corvera and Czech, 1998). AKT controls cell
survival, proliferation, and invasion via its numerous down-
stream targets (Stahl et al., 2004; Cheng et al., 2005; Meier
et al., 2005). The phosphoinositide phosphatase PTEN is the
physiological antagonist of PI3K signaling, as it catalyzes the
dephosphorylation of active phosphatidylinositol 3,4,5-tri-
phosphate to inactive phosphatidylinositol 4,5-biphosphate
(Stambolic et al., 1998). Besides being the most often
activated pathway in cancer in general, the PI3K/mTOR
pathway has also been shown to be frequently activated
in human melanoma (Meier et al., 2005; Karbowniczek
et al., 2007).
The pyridinylfuranopyrimidine PI-103 is a drug candidate
that has been the product of an extensive search for isoform-
specific PI3K inhibitors (Knight et al., 2006). Unlike other
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PI3K inhibitors, it selectively inhibits members of the
phosphoinositide-3-kinase-related kinase superfamily, namely
class I PI3Ks (with the lowest IC50 for p110a), mTORC1,
mTORC2, and DNA-PK, whereas leaving other members
such as ataxia telangiectasia mutated (ATM) or ataxia
telangiectasia and Rad3 related protein (ATR) unaffected
(Bain et al., 2007). Its high affinity for the p110a catalytic
subunit of PI3K is of particular interest, as p110a is the
principal insulin receptor substrate-1-associated PI3K in
cancer cell lines (Foukas et al., 2006). PI-103 has been
successfully employed in vitro and in animal models for
tumors such as glioma, Kaposi’s sarcoma and leukemia (Fan
et al., 2006; Chaisuparat et al., 2008; Kharas et al., 2008).
In the current study, we hypothesized that vertical
inhibition of the PI3K/AKT/mTOR signaling pathway by the
PI3K/mTORC1/mTOR2 triple inhibitor PI-103 alone and in
combination with the mTORC1 inhibitor rapamycin results in
potent anti-tumor activity against melanoma in vitro and
in vivo.
RESULTS
Blockade of PI3Ka and mTOR with PI-103 inhibits melanoma
cell viability
Cell viability following combined PI3Ka/mTORC1/mTORC2
inhibition by PI-103 was tested in a panel of different
melanoma cell lines. Cells were treated with PI-103 in the
dose range from 10nmol l1 to 10 mmol l1. Incubation with
PI-103 led to a dose-dependent decrease in cell viability in all
cell lines tested (i.e., Mel-Juso and 518A2 (Figure 1a), 607B,
A375, and SK-MEL-28 (Supplementary Figure S1 online)). The
IC50 values ranged from 0.05 (SK-MEL-28) to 0.8mmol l
1 (607B).
To investigate the effects of PI-103 on PI3K/mTOR signa-
ling, we performed phospho-specific western blot analyses of
AKT and ribosomal S6 protein (S6; Figure 1b)—two well-
described targets downstream of PI3K and mTOR (Soulard
and Hall, 2007). Concentrations below 0.05 and 0.5 mmol l1
in Mel-Juso and 518A2 cells, respectively, led to a slight
increase in AKT phosphorylation. Above these concentra-
tions, AKT phosphorylation was reduced and this effect
was stronger in Mel-Juso cells than in 518A2 cells, which
appeared to be relatively resistant to inhibition of AKT
phosphorylation. Phosphorylation of ribosomal S6 protein
was markedly reduced at 500 nmol l1 PI-103 in both
cell lines.
Rapamycin and PI-103 show synergistic effects on melanoma
cells in vitro
As relatively high concentrations of PI-103 were needed to
affect melanoma cell viability and phosphorylation of ribosomal
S6 protein and AKT, we next asked whether ‘‘vertical inhi-
bition’’ of the PI3K/mTORC1/mTOR2 by an additional inhibitor
might improve the activity of PI-103 against melanoma. Thus,
we treated Mel-Juso and 518A2 melanoma cells with combina-
tions of PI-103 and rapamycin, as rapamycin and its analogs are
the most potent mTORC1 inhibitors available. The combination
of rapamycin and PI-103 led to a more pronounced decrease in
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Figure 1. Effects of PI-103 on melanoma cells in vitro. (a) PI-103 inhibits viability of melanoma cells in vitro. Mel-Juso (black circles) and 518A2 (open squares)
melanoma cells were treated with PI-103 from 0.01–10mmol l1 for 72hours and viability assays were performed. Control treatment was with DMSO. Data show
mean values ± SD of four independent experiments. (b) PI-103 suppresses phosphorylation of phosphatidyl inositol 3-kinase downstream targets (phospho-specific
western blot). Mel-Juso and 518A2 cells were incubated with PI-103 (0.001–1mmol l1) for 24hours. ERK, extracellular signal-regulated kinase.
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cell viability in all the melanoma cell lines used compared with
the respective single-agent treatments, and resulted in a
statistically significant reduction in viability relative to the
respective single-agent treatments (P-values o0.05; Figure 2a
and Supplementary Figure S2 online). Combination indices
from isobolograms were calculated for all combinations. A
combination index below 1 indicates synergy between the two
drugs. The highest rates of synergy were observed for Mel-Juso,
518A2, and 607B cells (see Supplementary Figure S2 online).
We next examined whether the combination of PI-103 and
rapamycin affects the phosphorylation status of AKT and S6
protein in Mel-Juso and 518A2 cells. As shown in Figure 2b,
the combined treatment led to a synergistic reduction in
AKT phosphorylation. Rapamycin at 50 nmol l1 plus PI-103
at 0.5 mmol l1 completely inhibited AKT phosphorylation.
Treatment with rapamycin alone caused a clear increase in
AKT phosphorylation, as previously described in melanoma
and other cell lines (O’Reilly et al., 2006). Phosphorylation
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Figure 2. Effects of combined treatment with PI-103 and rapamycin on melanoma cells in vitro. (a) PI-103 and rapamycin synergistically reduce melanoma
cell viability. Mel-Juso and 518A2 cells were treated with rapamycin, PI-103, and combinations of the two inhibitors for 24 hours. Rapamycin was used at a
concentration of 50 nmol l1. Results of at least three independent experiments (viability assays) are depicted as box plots. Asterisks indicate significant
differences between the combined treatment and respective single-agent treatments (Po0.05). (b) Combination of rapamycin and PI-103 leads to suppression of
AKT phosphorylation at S473 and T308 (phospho-specific western blot). Mel-Juso and 518A2 cells were treated with rapamycin (50 nmol l1), PI-103
(0.1–1 mmol l1), and combinations of the two for 24 hours. Bands that were not originally run next to each other are separated by a dividing line. Control
treatment was with DMSO. (c) Combination of rapamycin and PI-103 leads to induction of cell-cycle arrest and apoptosis: Mel-Juso (white boxes) and 518A2
(gray boxes) cells were treated with rapamycin (50 nmol l1), PI-103 (1 mmol l1), and combination of the two for 48 hours. Cells were stained with propidium
iodide, and cell-cycle analysis was performed using flow cytometry. The fraction of apoptotic cells after 24 hours treatment was determined
using flow cytometry. Asterisks indicate that differences between combined treatments, and both single-agent therapies are significant. ERK, extracellular
signal-regulated kinase.
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of extracellular signal-regulated kinase was increased by
both agents alone and in combination. An increase in
extracellular signal-regulated kinase phosphorylation after
rapamycin treatment has also been observed by others
(Chen et al., 2010).
Combination of PI-103 and rapamycin led to a signi-
ficant increase of cells in the G0/G1 phase of the cell cycle
(Figure 2c). Treatment with rapamycin and PI-103 alone led
to a reduction in G2/M phase, whereas the combined
treatment also strongly suppressed the S-phase of the cell
cycle (see Supplementary Figure S4 online). With respect to
apoptosis induction, the effect of the combination treatment
with PI-103 and rapamycin was even more pronounced.
Whereas rapamycin treatment did not induce apoptosis and
PI-103 treatment led to modest increases in apoptosis, the
combination of PI-103 and rapamycin more than doubled the
number of apoptotic cells in both cell lines (Figure 2c).
Therefore, combination of PI-103 and rapamycin is strongly
synergistic in the induction of apoptosis in melanoma cells.
p110a inhibition is essential for the effects of PI-103
To gain more mechanistic insights into the observed effects, we
tested GDC-0941, which is a highly specific small-molecule
inhibitor of p110a, with reduced activity against mTOR and no
activity against DNA-PK (Raynaud et al., 2009). Mel-Juso and
518A2 were sensitive toward GDC-0941 treatment, with IC50
values of B0.75mmol l1 (Figure 3a). In combination with
rapamycin, synergistic reduction in cell viability was observed
to a similar extent as for PI-103 (Figure 3a and Supplementary
Figure S5 online). In addition, GDC-0941 treatment blocked
the phosphorylation of AKT protein (S473 and T308) at even
lower concentrations than PI-103, and S6 protein phosphor-
ylation was blocked at similar concentrations (Figure 3b).
Combination of GDC-0941 with rapamycin, analogous to
PI-103 plus rapamycin, completely blocked AKT and S6
protein phosphorylation at GDC-0941 concentrations as low
as 0.05mmol l1 (Figure 3b). Extracellular signal-regulated
kinase phosphorylation was not significantly influenced.
To elucidate the role of other p110 isoforms, we employed
IC87114, a highly specific p110d inhibitor, which—at higher
concentrations—also inhibits p110g (Ali et al., 2008). As
shown in Figure 3c, IC87114 had no effects on the viability of
Mel-Juso and 518A2 cells at concentrations that inhibit
p110d (around 0.1 mmol l1) and p110g (above 1 mmol l1;
only concentrations from 2.5–10 mmol l1 are shown), indi-
cating that other PI3K isoforms than p110a do not have a role
in the cell lines tested.
We next inhibited p110a using a small interfering RNA
(siRNA) directed against PIK3CA, the gene encoding the p110a
catalytic subunit of PI3K. PIK3CA siRNA treatment led to a
reduction in p110a protein levels byB50%, as determined by
densitometric analysis of western blot bands of p110a (Figure
3e). This p110a downregulation resulted in about 20%
reduction in cell viability in Mel-Juso and 518A2 cells, an
effect comparable to the treatment with rapamycin at
50nmol l1 alone (Figure 3d). Combination of PIK3CA siRNA
and rapamycin demonstrated a mild additive effect on cell
viability. At the protein level, PIK3CA siRNA further promoted
the reduction of pS6 by rapamycin, whereas it slightly reduced
the p-AKT induction caused by rapamycin (Figure 3e).
Rapamycin and PI-103 show synergistic effects in a human
melanoma xenograft model
To investigate the in vivo activity of combined rapamycin
and PI-103 treatment, we treated athymic nude mice
bearing 518A2 xenograft melanomas with rapamycin (in
the form of rapamune), PI-103, and the combination of both.
As shown in Figure 4a, both rapamycin and PI-103
monotherapy showed only modest effects on tumor growth.
In contrast, the combination treatment resulted in a major
inhibition of tumor growth by about 50% relative to any
other treatment group. At the end of the study, mice treated
with rapamycin plus PI-103 displayed a statistically signifi-
cant reduction in tumor volume compared with all other
treatment groups (Po0.05). None of the treatment regimens
resulted in observable toxicity for the animals. There were no
significant differences in body weight between the animals in
all the four groups over the whole course of the experiment
(Figure 4b).
To study the mechanism of action for the prominent anti-
tumor activity of rapamycin plus PI-103 in vivo, cell lysates
were prepared from tumors at the end of study and were
examined for PI3K/mTOR target expression. We observed a
clear effect of the combined treatment on AKT phosphoryla-
tion (Figure 4c). Similar to the in vitro results, rapamycin
treatment alone induced AKT phosphorylation in vivo, and
combination of PI-103 with rapamycin reversed this activa-
tion. After normalization for actin loading, densitometric
analysis revealed for the combination treatment a reduction
in AKT phosphorylation by B85 and 50% relative to
rapamycin and PI-103 monotherapies, respectively (Figure
4d). These findings were confirmed by immunohistochemical
analysis of tumor tissue sections. p-AKT and p-S6 protein
levels were clearly reduced following combined treatment
with PI-103 and rapamycin (Figure 4e).
DISCUSSION
Targeting the mTOR pathway appears to be a promising
strategy against numerous types of cancer and has already
been approved for the treatment of kidney cancer (Hudes
et al., 2007). Unfortunately, rapamycin and its analogs
(rapalogs) have not been successful in the treatment of
melanoma (Margolin et al., 2005). The reason for this lack of
response is not clear although it has been argued that the
ability of rapalogs to induce phosphorylation of the oncogene
AKT in certain cancer cells including melanoma might
hamper their efficacy (Hay, 2005). Targeting both, the PI3K
and mTOR, pathways with a set of newly identified ATP-
competitive PI3K/mTOR inhibitors inhibited the tumor
growth in a syngeneic B16 mouse melanoma tumor model
(Marone et al., 2009). Furthermore, combination of PI3K
inhibitors and rapamycin has shown cooperative effects in
other tumor entities in vitro (Takeuchi et al., 2005). In
contrast, horizontal inhibition using PI-103 and the BRAF
inhibitor sorafenib did not lead to synergistic effects against
melanoma in vivo (Lopez-Fauqued et al., 2009).
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In the present study, we hypothesized that ‘‘vertical
inhibition’’ of the PI3K/AKT/mTOR signaling pathway by
PI-103 and rapamycin results in potent anti-tumor activity
against human malignant melanoma in vitro and in vivo.
‘‘Vertical inhibition’’ refers to the optimal blockade of a given
pathway by combination of compounds that inhibit different
components within this pathway.
The combination of PI-103 with the highly specific
mTORC1 inhibitor rapamycin led to synergistic effects
in vitro and in vivo. Thus, the main finding of our work is
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Figure 3. Effects of inhibition of different p110 isoforms. (a) GDC-0941 and rapamycin show synergistic effects on cell viability. Mel-Juso and 518A2 cells
were treated with GDC-0941 (0.05–1 mmol l1) alone and in combination with rapamycin (50 nmol l1) for 72 hours, and cell viability assays of three
independent experiments were performed. Asterisks indicate significant differences between combination and respective single-agent treatments (Po0.05).
(b) Combination of rapamycin and PI-103 leads to the suppression of AKT phosphorylation (phospho-specific western blot). Mel-Juso and 518A2 cells were treated
with GDC-0941 from 0.05–1mmol l1 alone and in combination with rapamycin (50 nmol l1) for 24hours. Control treatment was with DMSO. (c) IC87114 has no
effect on cell viability. Mel-Juso (black circles) and 518A2 (open squares) cells were treated with IC87114 from 2.5–10mmol l1 for 72hours, and cell viability
assays of three independent experiments were performed. (d) p110a suppression and rapamycin show additive effects in inhibition of melanoma cell viability.
Mel-Juso (white bars) and 518A2 (black bars) cells were transfected with a small interfering RNA (siRNA) against p110a or control siRNA and treated with
rapamycin (all 50nmol l1) for 24hours, and cell viability assays of three independent experiments were performed. Asterisks indicate significant differences
between combination and respective single-agent treatments (Po0.05). (e) Combination of PIK3CA siRNA and rapamycin suppresses phosphorylation of AKT
(phosphorylation-specific western blot). Mel-Juso and 518A2 cells were treated wit PIK3CA siRNA, control siRNA, and rapamycin (all 50nmol l1) for 24hours.
Bands that were not originally run next to each other are separated by a dividing line. ERK, extracellular signal-regulated kinase.
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that vertical inhibition of the PI3K/mTORC1/mTORC2
signaling pathway with two distinct small molecule inhibitors
showed superior efficacy compared with the effects of either
agent alone.
In our melanoma model, relatively high PI-103 concen-
trations (between 0.5 and 1 mmol l1) were needed to
suppress AKT phosphorylation compared with other in vitro
models such as Kaposi’s sarcoma (Chaisuparat et al., 2008).
This relative resistance of the melanoma cells in our study
was overcome when we combined PI-103 with rapamycin.
Interestingly, low concentrations of PI-103 even led to
increases in p-AKT phosphorylation in both cell lines
(Figure 1b). This effect has also been observed with the
prototypic PI3K/mTOR inhibitor LY294002 (Werzowa et al.,
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Figure 4. Combination of rapamycin and PI-103 leads to synergistic effects in vivo. (a) Tumor volume (in mm3) of all the four treatment groups at the end of the
study. Each treatment group consisted of six animals. 518A2 cells were injected subcutaneously into athymic nude mice. Mice were treated five times weekly
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(treatment start) to the end of the study. (c) Cell lysates from excised tumors were analyzed using phospho-specific western blot analysis. (d) p-AKT band
intensities were measured using densitometry and were normalized with the respective actin bands. (e) Immunohistochemical staining of xenograft tumors
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2009). A possible explanation for this may be that at lower
concentrations, the PI3K and mTORC2 inhibition is not
sufficient to block the activating effect on AKT of mTORC1
inhibition.
When PI-103 and rapamycin were combined in vitro, the
phosphorylation of AKT was suppressed even at low PI-103
concentrations (Figure 2b). Synergistic suppression of cell
viability occurred even at much lower PI-103 concentrations
(Figure 2a), indicating that suppression of AKT phosphory-
lation alone cannot explain the synergistic effects of the
combination. 518A2 cells showed less response to PI-103 in
terms of reduction in AKT phosphorylation, but still the
effects on cell viability were greater. In this context, it is
noteworthy that the cell lines used differ in their PTEN status:
Mel-Juso cells are PTEN wild-type whereas 518A2 cells carry
a mutation (Wu et al., 2003; Werzowa et al., 2009). 607B
and A375 cells are PTEN wild-type and these cells were also
less sensitive to PI-103 compared with SK-MEL-28 cells,
which carry mutated PTEN (Tsao et al., 2000; Thallinger
et al., 2007). Overall, suppression of AKT phosphorylation
alone may not be an ideal biomarker for effectiveness of this
class of inhibitors, at least not in vitro.
The synergistic effects of PI-103 and rapamycin in vitro
and in vivo might be explained by the fact that these two
inhibitors exert their inhibitory actions via distinct molecular
mechanisms. Whereas PI-103 blocks the ATP-binding
domain of its targets, rapamycin exerts its action via a unique
and highly specific allosteric mechanism. First, it binds its
intracellular binding partner FK506 binding protein and then
the rapamycin-binding domain of mTORC1 probably result-
ing in an inhibition of substrate binding (Banaszynski et al.,
2005; Bain et al., 2007). It is therefore tempting to speculate
that the combination of these two distinct modes of action led
to optimal suppression of mTORC1 and PI3K class 1A, with
synergistic effects in vitro and in vivo. It also appears unlikely
that other targets of PI-103 such as DNA-PK are responsible
for the observed effects, as GDC-0941, a highly specific
inhibitor of p110a, had similar effects on cell viability and
protein phosphorylation (Figure 3a and b) at even lower
concentrations than PI-103. Importantly, GDC-0941 has little
activity against mTOR underscoring the fact that p110a but
not mTOR inhibition is mainly responsible for the anti-tumor
effects of PI-103. In general, mTOR inhibition seems less
important than p110a inhibition at least in cells with an
oncogenic mutation in PI3K signaling (Sutherlin et al., 2010;
Workman et al., 2010). GDC-0941 is currently undergoing
phase I clinical trials as anti-cancer drug (Workman et al.,
2010). In our study, the combination of p110a inhibition with
the allosteric mTORC1 inhibitor rapamycin yielded synergis-
tic effects on target protein phosphorylation and cell viability.
These data suggest that combination of rapamycin with GDC-
0941 seems to be a highly promising strategy for further pre-
clinical and clinical evaluation.
The results obtained with the siRNA directed against
PIK3CA support the finding that p110a is a relevant target
in melanoma cells and that combination with rapamycin
can augment the effects on viability and protein phosphory-
lation. Still, the effects of the siRNA were weaker than
the effects of PI-103 and GDC-0941, which might reflect the
incomplete downregulation of p110a protein levels by
PIK3CA siRNA.
Taken together, our study underscores the importance of
the PI3K/mTORC1/mTORC2 pathway in melanoma and
demonstrates that rational combination of compounds that
lead to an optimal blockade of a critical pathway (‘‘vertical
inhibition’’) may provide an effective strategy for future
treatment of melanoma.
MATERIALS AND METHODS
Reagents
PI-103 was kindly provided by Genentech (San Francisco, CA). For
experiments, fresh PI-103 solutions in DMSO were prepared before
use. We obtained rapamycin from Alexis Biochemicals (now Enzo
Life Sciences AG, Lausen, Switzerland). A 100mmol l1 stock
solution in DMSO was prepared and stored at 20 1C. Sirolimus
solution (Rapamune) was purchased from Wyeth Pharma (Madison,
NJ) and diluted to the desired concentration in PEG200. IC87114
and GDC-0941 were obtained from Selleck Chemicals LLC
(Houston, TX), dissolved in DMSO, and diluted to the desired final
concentration using cell culture media.
Cell lines
The human melanoma cell lines 518A2 and 607B were obtained
from P. Schrier (University of Leiden, The Netherlands). The cell line
Mel-Juso was kindly provided by Dr Judith Johnson (University of
Munich, Germany). A375 and SK-MEL-28 cells were obtained from
the American Type Culture Collection (ATCC; Manassas, VA). All
cells were cultured in Dulbecco’s modified eagle medium (Gibco
Invitrogen, Paisley, UK) with 4500mg l1 glucose, L-glutamine, and
pyruvate supplemented with 10% fetal calf serum, and an antibiotic
mixture containing penicillin, streptomycin, and amphotericin B
(Gibco Invitrogen) in a fully humidified 5% CO2, 95% ambient air
atmosphere at 37 1C.
Cell viability assay
The Cell Titer Blue cell viability assay (Promega, Madison, WI) was
used to quantify the fraction of viable cells in our samples. Tumor
cells in exponential growth were harvested and seeded at 2 103
cells per well (0.1ml) in 96-well plates and were incubated
overnight at 37 1C. The cells were then incubated for 24, 48, and
72 hours with the respective inhibitor. DMSO at the appropriate
concentrations was used as control. After treatment, 20 ml of cell titer
blue reagent was added and the reaction mixtures were incubated
for 3 hours at 37 1C. Color reactions were measured using a
fluorescence detection system (Victor 1620 Multilabel Detector,
Wallac/Perkin Elmer, Wellesley, MA).
siRNA transfection
In all, 7.5 104 cells were seeded 1 day before transfection in six-
well plates in cell culture medium without antibiotics. Cells were
transfected with 50 nmol l1 Silencer Select siRNA against PIK3CA
(p110a catalytic subunit of PI3K; Ambion, Austin, TX) in the
presence of Saint-Red siRNA delivery system according to the
manufacturer’s instructions (Synvolux, Groningen, The Netherlands).
As control, a Silencer Select Negative Control at 50 nmol l1 was
employed (Ambion/Applied Biosystems, Austin, TX).
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Western blotting
Cell extracts were prepared in lysis buffer containing 100mmol l1
NaCl, 0.1% SDS, 1% Nonidet P40, 50mM Tris, pH 7.4, 10mmol l1
EDTA, supplemented with 10mmol l1 p-nitrophenolphosphate,
40mmol l1 b-glycerophosphate, and Complete protease inhibitor
cocktail tablets (Roche, Mannheim, Germany). The amount of
soluble proteins was quantified by means of modified Bradford
analysis (Bio-Rad, Richmond, CA). Total lysates (10 mg per lane)
were separated by electrophoresis through a 7.5, 12, or 15% SDS
polyacrylamide gel and were blotted onto nitrocellulose membranes
(Whatman, Dassel, Germany). Membranes were blocked with 0.2%
I-Block (Tropix, Bedford, MA) in 1 Tris-buffered saline plus 0.1%
Tween 20 and incubated with the primary antibodies at 4 1C
overnight. The primary antibody against actin was purchased from
Sigma (St Louis, MI). The antibodies against total and phospho-
(Ser473) and phospho-(T308) AKT, total and phospho-(Ser240þ 244) S6,
total and phospho-(Thr202/Thyr204) p44/42 mitogen-activated protein
kinase, and PI3 kinase p110a were obtained from Cell Signaling
Technology (Beverly, MA). The membranes were washed and
incubated again for 30minutes at room temperature with alkaline
phosphatase-conjugated goat anti-mouse and goat anti-rabbit
immunoglobulins (Tropix). The bound antibody was detected using
an enhanced chemiluminescence reagent (Tropix). Band intensities
were quantified using TotalLab software (Nonlinear Dynamics,
Newcastle upon Tyne, UK).
Apoptosis assay
For quantification of apoptosis, a PE-conjugated monoclonal
Apo2.7 antibody (Beckman-Coulter, Fullerton, CA) was used.
After treatment, 0.5–1.0 106 cells were detached from six-well
plates using accutase (PAA, Linz, Austria) and then washed twice
with ice-cold Dulbecco’s phosphate-buffered saline (DPBS; Lonza,
Vervier, Belgium). Cells were permeabilized with cold (4 1C)
digitonin (Sigma) at 100mgml1 in DPBSF (DPBS with 2.5% fetal
calf serum (v/v) and 0.01% NaN3 (w/v)) for 20minutes. After
washing, 20 ml of Apo2.7-PE and 80 ml of DPBSF were added and
the mixture was incubated for 15minutes at room temperature in
the dark. After a washing step, the cells were suspended in DPBSF
and analyzed using the FACScalibur device (BD biosciences,
San Jose, CA).
Cell-cycle distribution
For cell-cycle measurements, cells were seeded in six-well plates
(80,000 per well), treated with therapeutics of interest, harvested in
log-phase, and detached with Trypsin (Gibco Invitrogen). The
suspension was centrifuged at 2500 r.p.m. for 5minutes at room
temperature, pellets were washed once with DPBS, resuspended in
200ml DPBS, and fixed by adding 2ml of ice-cold ethanol-DPBS mix
(70:30). After 30minutes on ice, fixed cells were centrifuged at
1200 r.p.m. for 5minutes at room temperature, supernatant was
discarded, cells were resuspended in 800ml DPBS, 10 ml of RNase A
was added, cells were stained with 10 ml of propidium iodide and
incubated for at least 30minutes at 37 1C. Following this procedure,
samples were protected from light and analyzed directly with the
FACScalibur device.
FACS data were further analyzed using ModFIT software (Verity
software house, Topsham, ME) to determine the relative amounts of
cell-cycle phases.
Xenografts
518A2 human melanoma cells (107) were resuspended in DPBS and
injected subcutaneously into lower flanks on both sides of 8- to 10-
week-old female athymic nude mice (Harlan Winkelmann, Borchen,
Germany). Mice with established tumors (50–100mm3) were
randomly allocated to treatment with PI-103 (20mg kg1 per day
in DMSO, administered intraperitoneally), sirolimus (1mg kg1 per
day in PEG200, administered per os by oral gavage), combination of
the two or solvent control (PEG200 plus DMSO). Animals were
treated five times a week and tumors were measured with callipers
twice a week. Volumes were measured from six mice on both sides
for each data point (mm3¼ 4/3 3.142 (width2  length/2).
When tumor size in control group reached abortion criteria (day 33
after initiation of treatment), all animals were killed and tumors were
snap frozen for extraction of protein lysates. The study protocol was
approved by the Medical University of Vienna Animal Welfare
Committee. All animal studies were performed according to the
Austrian laws and guidelines for animal care and protection.
Immunohistochemistry
Paraffin-embedded mouse tissue sections were stained for p-AKT
(Ser473) and p-S6 (Ser240þ 244; Cell Signaling Technology) and a
DAKO LSAB 2 system.
Statistical analysis
Data were expressed as the mean± SD. The statistical analysis was
done using Student’s t-test. For multiple comparisons, analysis of
variance was followed by the least significant difference post-hoc
test. P-values o0.05 were considered statistically significant.
Statistical analysis was performed using SPSS 13 software (SPSS,
Chicago, IL). For evaluation of synergistic effects and calculation of
combination indices, CalcuSyn Version 1.1 Software (Biosoft,
Cambridge, UK) was used.
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